来自MSN2 个月
FDA Issues Safety Alert on Liver Disease Drug
The FDA in 2016 granted accelerated approval to the farnesoid X receptor (FXR) agonist as a second-line treatment for adults with PBC, either in combination with ursodeoxycholic acid (UDCA ...
CNN3 年
Terns Pharmaceuticals, Inc.
The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was ...